JP2022527482A - 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 - Google Patents

尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 Download PDF

Info

Publication number
JP2022527482A
JP2022527482A JP2021557790A JP2021557790A JP2022527482A JP 2022527482 A JP2022527482 A JP 2022527482A JP 2021557790 A JP2021557790 A JP 2021557790A JP 2021557790 A JP2021557790 A JP 2021557790A JP 2022527482 A JP2022527482 A JP 2022527482A
Authority
JP
Japan
Prior art keywords
eldaphytinib
treatment
patient
patients
fgfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527482A5 (https=
JPWO2020201138A5 (https=
Inventor
ポレ，ピーター マリー ゼット デ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2022527482A publication Critical patent/JP2022527482A/ja
Publication of JP2022527482A5 publication Critical patent/JP2022527482A5/ja
Publication of JPWO2020201138A5 publication Critical patent/JPWO2020201138A5/ja
Priority to JP2025230741A priority Critical patent/JP2026048748A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021557790A 2019-03-29 2020-03-27 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 Pending JP2022527482A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025230741A JP2026048748A (ja) 2019-03-29 2025-12-04 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
EP19166429.1 2019-03-29
US201962833395P 2019-04-12 2019-04-12
US62/833,395 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025230741A Division JP2026048748A (ja) 2019-03-29 2025-12-04 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2022527482A true JP2022527482A (ja) 2022-06-02
JP2022527482A5 JP2022527482A5 (https=) 2024-07-24
JPWO2020201138A5 JPWO2020201138A5 (https=) 2024-07-24

Family

ID=69954076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021557790A Pending JP2022527482A (ja) 2019-03-29 2020-03-27 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP2025230741A Pending JP2026048748A (ja) 2019-03-29 2025-12-04 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025230741A Pending JP2026048748A (ja) 2019-03-29 2025-12-04 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Country Status (15)

Country Link
US (1) US20220175768A1 (https=)
EP (2) EP4548935A3 (https=)
JP (2) JP2022527482A (https=)
KR (1) KR20210143878A (https=)
CN (1) CN113645975A (https=)
AU (1) AU2020253054B2 (https=)
BR (1) BR112021019203A2 (https=)
CA (1) CA3130773A1 (https=)
IL (1) IL286727A (https=)
JO (1) JOP20210260A1 (https=)
MA (1) MA55486A (https=)
MX (1) MX2021011943A (https=)
PH (1) PH12021552352A1 (https=)
SG (1) SG11202109854RA (https=)
WO (1) WO2020201138A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002980A (es) * 2020-09-14 2023-06-06 Janssen Pharmaceutica Nv Terapias de combinación de inhibidores del fgfr.
KR20240019293A (ko) * 2021-06-07 2024-02-14 알.피.쉐러 테크놀러지즈 엘엘씨 습기 감응성 약학 조성물용 보호 코팅
EP4415692A1 (en) 2021-10-12 2024-08-21 TARIS Biomedical LLC Erdafitinib formulations and systems for intravesical administration
CN119072311A (zh) 2022-02-18 2024-12-03 塔里斯生物医药公司 用于膀胱内施用的厄达替尼制剂和渗透系统
CN116106240B (zh) * 2022-12-26 2025-11-07 华中农业大学 一种尿液酪氨酸检测体系、检测方法及检测试剂盒
CN120731076A (zh) 2023-02-13 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
JP2026506041A (ja) 2023-02-17 2026-02-20 タリス バイオメディカル エルエルシー 膀胱がんの治療における使用のための膀胱内投与のためのエルダフィチニブ

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018141921A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment

Also Published As

Publication number Publication date
KR20210143878A (ko) 2021-11-29
PH12021552352A1 (en) 2022-09-05
JP2026048748A (ja) 2026-03-17
EP4548935A2 (en) 2025-05-07
EP3946340A1 (en) 2022-02-09
MA55486A (fr) 2022-02-09
BR112021019203A2 (pt) 2021-11-30
SG11202109854RA (en) 2021-10-28
WO2020201138A1 (en) 2020-10-08
MX2021011943A (es) 2021-11-03
CA3130773A1 (en) 2020-10-08
JOP20210260A1 (ar) 2023-01-30
AU2020253054B2 (en) 2026-01-08
IL286727A (en) 2021-10-31
CN113645975A (zh) 2021-11-12
EP4548935A3 (en) 2025-08-06
AU2020253054A1 (en) 2021-09-30
US20220175768A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JP2022527482A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
JP2021008475A (ja) Ｈｅｒ２増幅性癌の処置のための方法
US20230110113A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US20250177414A1 (en) Combination therapies for treatment of breast cancer
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
JP2026505598A (ja) 高リスク筋層非浸潤性膀胱癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240610

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250404

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250805